Ortho Clinical Diagnostics Holdings

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions. Because Every Test is a LifeTM, we never stop innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care. As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, we proudly serve the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ortho-Clinical Diagnostics is a manufacturer of medical equipment. They provide hospitals, hospital networks, clinical laboratories, and blood banks. They specialize in in vitro diagnostics and are dedicated to improving them through laboratory testing and blood-typing solutions.

QuidelOrtho Corp

Quidel will acquire OCDX stock for $24.68 per share and newly issued stock. The transaction will be worth a total of $6 billion.

OCDX Stock Alert: 9 Things to Know About the Quidel Deal Sending Ortho Clinical Higher

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) to Quidel Corporation is fair to Ortho shareholders. Under the terms of the proposed agreement, Ortho shareholders will receive $7.14 in cash per common share and 0.1055 shares of common stock in the combined company for each Ortho common share, with Ortho shareholders expected to own approximately 38% of the combined company

Ortho Clinical (OCDX) Stock Alert: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Ortho Clinical Diagnostics Holdings PLC Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – OCDX

The shares of Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) are up 8.1% to trade at $21.45 last check, after news that Quidel (QDEL) will acquire the company for roughly $6 billion in a cash-and-stock deal -- expanding its portfolio of diagnostic products.

Medical Equipment Stock Surges on Buyout Buzz

JD.com

Find out why the stock market could see more gains.

JD.com Is Falling, But an M&A Bid Is Lifting This Small Nasdaq Stock Thursday

Quidel Corp (NASDAQ: QDEL) has agreed to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share in cash and newly issued shares in the combined company,  The offer price represents a 25% premium over Ortho's closing price on December 22, 2021.

Quidel To Buy Ortho Clinical Diagnostics For $24.68/Share: Highlights

Quidel Corp. QDEL, -0.42% said Thursday it agreed to acquire Ortho Clinical Diagnostics Holdings Plc OCDX, +1.54% for $24.68 per share of common stock in cash and newly issued shares in the combined company. The price amounts to a 25% premium over Ortho's closing price on Wednesday and an equity value of about $6 billion.

Quidel buying Ortho Clinical Diagnostics in $6 billion deal

SAN DIEGO & RARITAN, N.J.--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world's largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho's closing price on December

Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics

RARITAN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) --  Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021, with a fireside chat scheduled for 3:30pm ET.

Ortho Clinical Diagnostics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

Ortho Clinical Diagnostics Holdings plc (OCDX) CEO Chris Smith on Q3 2021 Results - Earnings Call Transcript

Doximity

OCDX vs. DOCS: Which Stock Is the Better Value Option?

OCDX or DOCS: Which Is the Better Value Stock Right Now?

RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday, November 3, 2021.

Ortho Clinical Diagnostics to Report Third Quarter 2021 Results on November 3, 2021

Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was ranked No.

Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year

New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced the availability of Immediate Spin Crossmatch (ISXM) on the company's ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.

Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities

RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today announced the closing (the “Closing”) of the previously announced underwritten secondary offering of 25,300,000 of the Company's ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the “Selling Shareholder”), which includes the full exercise by the underwriters of their option to purchase up to 3,300,000 additional ordinary shares, at a price of $17.50 per share. As a result of the Closing, the Company is no longer a “controlled company” within the meaning of the rules of the NASDAQ Global Select Market.

Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Company's ordinary shares held by a selling shareholder affiliated with The Carlyle Group (the “Selling Shareholder”) at a price of $17.50 per ordinary share. The offering is expected to close on September 14, 2021, subject to customary closing conditions. The Selling Shareholder granted the underwriters a 30-day option to purchase up to 3,300,000 additional ordinary shares of the Company at the public offering price less the underwriting discount.

Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world's largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the “Selling Shareholder”), an affiliate of The Carlyle Group, intends to offer for sale in an underwritten secondary offering 22,000,000 ordinary shares of the Company pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ordinary shares on the same terms and conditions.

Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming investor conferences:

Ortho Clinical Diagnostics to Participate in September Investor Conferences

Ortho Clinical Diagnostics Holdings plc (OCDX) CEO Chris Smith on Q2 2021 Results - Earnings Call Transcript

-- Ortho's new VITROS® Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection.  -- Ortho is the first company to have an EUA for both a quantitative IgG antibody assay targeting the spike protein and a total assay targeting the nucleocapsid protein.

Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test

Strong Revenue Growth Drives Financial Results

Ortho Clinical Diagnostics Reports Second Quarter 2021 Results

RARITAN, N.J., July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in Canada.

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.

Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021

RARITAN, N.J., July 22, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS® Critical Care menu, is now available in EU Countries, U.K. and several ASPAC and LATAM countries.

Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu

The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics' (NASDAQ: OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test. The company says it the first quantitative COVID-19 IgG antibody test to receive a EUA nod.

Ortho Clinical Diagnostics' COVID-19 Antibody Test Gets FDA Emergency Use Approval

- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measu re antibody response to SARS-CoV-2 - Ortho is the only company that offers laboratories in the U.S. a quantitative IgG test to the spike protein in addition to a total antibody test to the nucleocapsid protein RARITAN, N.J., July 9, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

News for Ortho Clinical Diagnostics Holdings Stock (OCDX)